Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Apr 18, 2015 (11 years ago)

Librax (5 mg chlordiazepoxide HCl and 2.5 mg clidinium bromide)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Librax (5 mg chlordiazepoxide HCl and 2.5 mg clidinium bromide) capsules, 100-count bottle, Rx Only, Manufactured in Canada by: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7 Canada; Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807, NDC 0187-4100-10.

Affected NDC 0187-4100-10

Compare with the code on your package — it is the most precise check available.

Drug: Chlordiazepoxide

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Librax
Chlordiazepoxide Hydrochloride and Clidinium Bromide
NDC 00187-4100
CHLORDIAZEPOXIDE HYDROCHLORIDE 5 mg/1; CLIDINIUM BROMIDE 2.5 mg/1 Capsule
Oral
Bausch Health US, LLC Rx
Recalling firm
Valeant Pharmaceuticals North America LLC
NDC code
0187-4100-10
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1034-2016 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Chlordiazepoxide recalls

See all
Class II · Moderate risk

chlordiazePOXIDE HCl

Labeling: Label Mixup: chlordiazePOXIDE HCl, Capsule, 25 mg may have potentially been mislabeled as one of the following drugs: FLECAINIDE ACETATE, Tablet, 50 mg, NDC 65162064110, Pedigree: AD46414_16, EXP: 5/16/2014; CALCIUM ACETATE, Capsule, 667 mg, NDC 00054008826, Pedigree: AD49463_1, EXP: 5/16/2014; LACTOBACILLUS GG, Capsule, 0 mg, NDC 49100036374, Pedigree: W003173, EXP: 6/13/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-950-2014

Other recalls by Valeant Pharmaceuticals North America LLC

All 2015 recalls
Class III · Low risk

Diltiazem HCl CD capsules

Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Terminated Dissolution failure Valeant Pharmaceuticals North America LLC NDC 68682-521-01 D-0491-2019
Class III · Low risk

Cardizem CD

Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Terminated Dissolution failure Valeant Pharmaceuticals North America LLC NDC 0187-0798-30 D-0490-2019
Class III · Low risk

Cardizem CD

Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Terminated Dissolution failure Valeant Pharmaceuticals North America LLC NDC 0187-0797-30 D-0489-2019
Class III · Low risk

Cardizem CD

Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Terminated Dissolution failure Valeant Pharmaceuticals North America LLC NDC 0187-0796-30 D-0488-2019